Showing 1611-1620 of 1774 results for "".
- Topcon Healthcare Appoints Christian Odaker as Chief Technology Officerhttps://modernod.com/news/topcon-healthcare-appoints-christian-odaker-as-chief-technology-officer/2482599/Topcon Healthcare announced the appointment of Christian Odaker, PhD, to the role of Chief Technology Officer (CTO). Dr. Odaker willsupport the company's 'Healthcare from the Eye' initiative, which leverages AI-powered disease detection and management using da
- Johnson & Johnson to Showcase Tecnis Odyssey IOL and Present New Research at AAO 2024https://modernod.com/news/johnson-johnson-to-showcase-tecnis-odyssey-iol-and-present-new-research-at-aao-2024/2482501/Johnson & Johnson will highlight its latest innovations in eye health during the 2024 American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21 in Chicago. Among the company's spotlight advancements is the Tecnis Odyssey IOL, a new presbyopia-correcting IOL t
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show
- J&J Expands Availability of Tecnis Odyssey PC-IOLhttps://modernod.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built
- Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring Apphttps://modernod.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/Tilak Healthcare is launching a pilot program in the US with Novartis for OdySight, Tilak’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- Allergan, Sightsavers, and the IAPB Announce the “Keep Sight” Initiative to Address Glaucoma in Ganjam, Odishahttps://modernod.com/news/allergan-sightsavers-and-the-iapb-announce-the-keep-sight-initiative-to-address-glaucoma-in-ganjam-odisha/2477318/Allergan, Sightsavers, and the International Agency for the Prevention of Blindness (IAPB) announced the launch of its unique joint initiative, ‘Keep Sight India,’ a community-based glaucoma screening program to prevent glaucoma-related vision loss in Ganjam District, Odisha. The pilot kicked off
- Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directorshttps://modernod.com/news/nicox-appoints-jean-francois-labbe-as-chairman-of-the-board-of-directors/2481001/Nicox announced that Jean-Francois Labbé, a board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022. Michele Garufi, who has filled the role ad interim since June 1, 2022, will remain as a Board member. “I am ta
- Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol Eye Drops for Night Vision Disturbanceshttps://modernod.com/news/ocuphire-announces-positive-topline-results-from-lynx-1-phase-3-trial-evaluating-nyxol-eye-drops-for-night-vision-disturbances/2480873/Ocuphire Pharma announced positive topline results from the LYNX-1 phase 3 pivotal clinical trial investigating its product candidate Nyxol for night (or dim light) vision disturbances (NVD). More than 650 subjects have now been exposed to Nyxol. NVD is a condition i
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb